. . . . . "A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma"@en . . . . . . . . . . . . . . . . . . . . "clinical trial"@en . . "1500"^^ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "klinisch onderzoek"@nl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "NCT01274338" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery"@en . "Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery"@en . . . "2011-05-25T00:00:00Z"^^ . . . . . . . . . . . . . . . . . . . . . . . . "12"^^ . . . . . . . . . . . . . . . . . . . . . . . . . . . "ensayu cl\u00EDnicu"@ast . . . . "2020-05-01T00:00:00Z"^^ . . . . . . . . . . . . . . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . "Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery"@en . . . . . . . . .